Dr. Pecora on CTLA-4 and PD-1 Combinations in Multiple Myeloma

Exploring the Combination Anti-CTLA-4 and Anti-PD-1 in Multiple Myeloma Post-TransplantПодробнее

Dr. Pecora on Updated MAIA Data in Multiple MyelomaПодробнее

Dr. Pecora on the CPIT001 Study in Hematologic MalignanciesПодробнее

Anti-PD-1 or anti-CTLA-4 in first line therapy?Подробнее

PD1/ CTLA4 : Upfront or sequentially?Подробнее

Combining immunotherapies: inhibiting the CTLA-4 and PD-1 pathwaysПодробнее

Dr. Adams on the Utility of Combination CTLA-4 and PD-1 Blockade in Breast CancerПодробнее

Dr. Pecora on the Significant Results of CTLA-4 and PD-1 Combination in Multiple MyelomaПодробнее

Combining CTLA-4 Agents With PD-1/PD-L1 Agents in Lung CancerПодробнее

Dr. Pecora on Patient Management Payments Under the OCMПодробнее

Dr. Pecora Discusses New PARP Inhibitor For Ovarian CancerПодробнее

Dr. Pecora on the Role of Stem Cell Transplant in Patients With Multiple MyelomaПодробнее

The Rationale for Initiating Therapy with an Immuno-Oncology DrugПодробнее

How does the combination of CTLA-4 and PD-1 agents enhance treatment outcomes for melanoma patients?Подробнее

Unite To Cure: Andrew Pecora, MDПодробнее

CheckMate 227: Combining CTLA-4 and PD-L1 in NSCLCПодробнее

Dr. Pecora on his Personal Involvement in ResearchПодробнее

Monoclonal antibodies and checkpoint inhibitors for multiple myelomaПодробнее

Regional Cancer Care Associates - Dr. Pecora on Findings from the HPV Cervical Cancer StudyПодробнее